Hyperthermic Intrathoracic Chemotherapy and Photodynamic Therapy: A Single-Institution Experience for Malignant Pleural Diseases
Oncology · 2025
DOI: 10.1159/000549055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2025. Verfasst von Yu-An Zheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Surgery, Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, …. Hauptthemen laut MEDLINE: Photochemotherapy, Hyperthermia, Induced, Pleural Neoplasms, Lung Neoplasms. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Hyperthermic intrathoracic chemotherapy (HITHOC) is an intraoperative treatment that involves the perfusion of heated chemotherapy agents within the thoracic cavity. Photodynamic therapy (PDT) utilizes systemically administered photosensitizing agents and targeted light exposure to eliminate residual cancer cells during the surgery. This study aimed to present our experience with local therapies in the management of pleural malignancies, describe the respective outcomes of each modality, and make a preliminary comparison.
Methods
We retrospectively and consecutively enrolled patients with advanced intrathoracic cancer (lung cancer, mesothelioma, and thymoma) with pleural involvement who underwent surgical resection followed by HITHOC or PDT at a single medical center between June 2005 and December 2022. Patients with extrathoracic metastases were excluded. The primary outcomes assessed were mortality rates and overall survival (OS), while the secondary outcomes included recurrence rates and progression-free survival (PFS).
Results
Seventy patients were included, with 15 undergoing HITHOC and 55 undergoing PDT. No significant differences were observed in terms of age, gender, or pathological stage between the two groups. Perioperative parameters, including operative time, estimated blood loss, postoperative length of stay, and intensive care unit stay duration, did not differ significantly between groups. Among patients with recurrence, 50% had localized disease within the chest cavity. HITHOC showed a 3-year OS of 70.5% and 2-year PFS of 46.8% (median follow-up 18.33 months), while PDT showed a 5-year OS of 53.4% and 5-year PFS of 25.5% (median follow-up 73.07 months).
Conclusions
The clinical outcomes of our cohort are comparable to previous studies. Our preliminary data also suggest that HITHOC and PDT may have similar efficacy in treating pleural malignancies. However, the long-term outcomes associated with different neoadjuvant and adjuvant therapies remain unidentified.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Thoracic Surgery, Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
- Division of Thoracic Surgery, Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, jangminglee@gmail.com.
Zitieren
APA
Zheng, Y. A., Chen, K. C., Huang, P. M., Lin, M. W., Kuo, S. W., & Lee, J. M. (2025). Hyperthermic Intrathoracic Chemotherapy and Photodynamic Therapy: A Single-Institution Experience for Malignant Pleural Diseases. Oncology. https://doi.org/10.1159/000549055
Vancouver
Zheng YA, Chen KC, Huang PM, Lin MW, Kuo SW, Lee JM. Hyperthermic Intrathoracic Chemotherapy and Photodynamic Therapy: A Single-Institution Experience for Malignant Pleural Diseases. Oncology. 2025. doi:10.1159/000549055
BibTeX
@article{Zheng2025,
author = {Zheng, Yu-An and Chen, Ke-Cheng and Huang, Pei-Ming and Lin, Mong-Wei and Kuo, Shuenn-Wen and Lee, Jang-Ming},
title = {Hyperthermic Intrathoracic Chemotherapy and Photodynamic Therapy: A Single-Institution Experience for Malignant Pleural Diseases},
journal = {Oncology},
year = {2025},
doi = {10.1159/000549055}
}
EUVIMED